BC and NR contributed equally to this work.
Peripheral blood stem cell collection in low-weight children: retrospective comparison of two apheresis devices
Article first published online: 10 OCT 2013
© 2013 American Association of Blood Banks
Volume 54, Issue 5, pages 1371–1378, May 2014
How to Cite
Cherqaoui, B., Rouel, N., Auvrignon, A., Defachelles, A.-S., Deméocq, F., Kanold, J. and Merlin, E. (2014), Peripheral blood stem cell collection in low-weight children: retrospective comparison of two apheresis devices. Transfusion, 54: 1371–1378. doi: 10.1111/trf.12448
- Issue published online: 12 MAY 2014
- Article first published online: 10 OCT 2013
- Manuscript Accepted: 27 AUG 2013
- Manuscript Revised: 20 AUG 2013
- Manuscript Received: 13 MAY 2013
Apheresis is a major challenge in peripheral stem cell collection from low-weight children with cancer. Comparisons between the new apheresis device Optia (TerumoBCT) and the earlier COBE Spectra (CaridianBCT) have been performed in adults but not in low-weight children. The objective was to compare the performance of these two devices in small children.
Study Design and Methods
In this retrospective study, all patients were reviewed weighing less than 15 kg undergoing stem cell collection using the Optia device between April 2011 and April 2012. They were paired on weight in a 3:1 ratio with patients whose cells had been collected with the COBE Spectra since 2006.
Six patients were treated with the Optia and were matched with 18 patients treated with the Spectra. No side effects occurred. Collection efficiency (CE) was similar between the two groups (50% vs. 47%), but CD34 cell blood clearance was lower with the Optia (0.4 mL/min/kg vs. 0.6 mL/min/kg, p < 0.01). Platelet (PLT) loss and hemoglobin (Hb) loss were significantly reduced with the Optia (respectively, 32% vs. 54%, p < 0.01; and 1.4 g/dL vs. 2.9 g/dL, p < 0.01). Apheresis duration was increased with the Optia (159 min vs. 134 min, p < 0.05). The cell product harvested with the Optia had a lower volume and lower hematocrit, but similar white blood cell and PLT content.
Compared with the Spectra, the Optia allows similar CE with a reduced PLT and Hb loss but with a longer duration.